Tega Industries completes $1.5bn Molycop acquisition with Apollo Funds as TEGA scales global mining consumables platform
Read More Pharma Industry News AstraZeneca Q1 2026 results: Can oncology and rare disease growth keep AZN’s 2030 ambition on track? AstraZeneca’s growth engine is firing, but pricing pressure and launch risk still loom. Can oncology and rare disease carry AZN to 2030? byVenkateshApril 29, 2026